Long-Term Safety and Efficacy of a Water-Free Cyclosporine 0.1% Ophthalmic Solution for Treatment of Dry Eye Disease: ESSENCE-2 OLE

期限(时间) 医学 疾病 眼科 内科学 物理 量子力学
作者
David Wirta,Anat Galor,Carol Aune,Patrick Vollmer,Eva Liang,Alice S. Meides,Sonja Krösser
出处
期刊:Cornea [Lippincott Williams & Wilkins]
标识
DOI:10.1097/ico.0000000000003567
摘要

Purpose: The ESSENCE-2 Open-Label Extension study aimed to demonstrate long-term safety, tolerability, and efficacy of a novel water-free, nonpreserved topical cyclosporine 0.1% ophthalmic solution (US brand name VEVYE) for patients with dry eye disease (DED). Methods: This was a Phase 3, prospective, multicenter, open-label, clinical study. All patients received cyclosporine 0.1% ophthalmic solution and dosed each eye twice a day for 52 weeks. Primary safety end points were ocular and nonocular adverse events (AEs). Secondary safety end points included visual acuity, biomicroscopy, intraocular pressure, and dilated fundoscopy. Efficacy end points, such as total corneal fluorescein staining (tCFS) score (National Eye Institute [NEI] Scale), ocular symptoms (visual analog scale [VAS]), and Schirmer tear test, were also assessed. Results: A total of 202 patients were enrolled from the ESSENCE-2 study. At week 52, 175 patients (86.6%) completed ESSENCE-2 open-label extension. A total of 55 patients (27.5%) reported 74 ocular treatment-emergent adverse events (TEAEs). The most common ocular AE was instillation site pain (6.5%), which was of mild intensity in all cases. Patients showed statistically significant improvements in all prespecified efficacy end points compared with baseline at each visit. Corneal staining improvements were early and stabilized over time while tear production improved continuously. Symptomatology improvement followed these effects with scores reaching a minimum after 1 year of treatment. Conclusions: The water-free cyclosporine 0.1% ophthalmic solution was safe and well tolerated during long-term use. The results demonstrated sustained 1-year efficacy, in both signs and symptoms of DED, and may help understand short and long-term healing dynamics in a predominant inflammatory DED population.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
共享精神的应助被学阿斗采纳,获得10
刚刚
传奇3的应助被风笛采纳,获得10
刚刚
1秒前
paul发布了新的文献求助10
1秒前
1秒前
wsg发布了新的文献求助10
1秒前
1秒前
陈永伟发布了新的文献求助10
2秒前
水煮电吹风的应助被rururu采纳,获得10
2秒前
风吹麦浪的应助被忧心的翎采纳,获得10
3秒前
3秒前
3秒前
小蘑菇的应助被乐观紫霜采纳,获得10
4秒前
4秒前
自由念之完成签到,获得积分10
4秒前
vv完成签到,获得积分10
5秒前
zhichi发布了新的文献求助10
5秒前
goujuan完成签到,获得积分10
5秒前
大模型的应助被Lizhiiiy采纳,获得10
5秒前
Jerry完成签到,获得积分10
5秒前
六六发布了新的文献求助30
5秒前
5秒前
6秒前
xgj完成签到,获得积分10
6秒前
慧慧完成签到,获得积分10
6秒前
zcx发布了新的文献求助10
6秒前
DoctorG发布了新的文献求助10
6秒前
研友_VZG7GZ的应助被wwwwwww采纳,获得10
6秒前
7秒前
besatified的应助被hdbys采纳,获得10
7秒前
AireenBeryl531举报椰子云的求助涉嫌违规
7秒前
7秒前
我是老大的应助被wsg采纳,获得30
8秒前
9秒前
Orange的应助被helly采纳,获得30
9秒前
慧慧发布了新的文献求助30
9秒前
可爱的香菇完成签到 ,获得积分10
9秒前
9秒前
小马甲的应助被小李吃小孩采纳,获得10
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181155
求助须知:如何正确求助?哪些是违规求助? 9571140
关于积分的说明 21816740
捐赠科研通 7777528
什么是DOI,文献DOI怎么找? 3433436
关于科研通互助平台的介绍 2557664
邀请新用户注册赠送积分活动 2479482